SingleCell Biotechnology
Development of phenotype assays that target aggressive and invasive cancer stem cells.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $2.5m | Grant | |
| Total Funding | 000k | ||
Related Content
SingleCell Biotechnology operates in the biotechnology sector, focusing on the development of phenotype assays that target aggressive and invasive cancer stem cells. The company's platform is designed to recapitulate dormancy, migration, and single-cell clonogenicity of tumor stem cells, which are key characteristics of cancers responsible for recurrence and mortality. This platform is instrumental in collecting high-content and high-throughput data, essential for drug discovery and disease analysis. SingleCell Biotechnology's assays are applicable to all solid tumor cancer cells, with demonstrated use in Glioblastoma and Breast Cancer. The business model involves partnering with pharmaceutical companies and research institutions to screen drug libraries and identify druggable targets, thereby expediting and de-risking the drug development process. Revenue is generated through collaborations and partnerships aimed at advancing the use of their platform in drug development. The company has been awarded a CPRIT Grant to optimize its assays for Glioblastoma, highlighting its commitment to advancing cancer treatment. Keywords: phenotype assays, cancer stem cells, drug discovery, disease analysis, solid tumors, Glioblastoma, Breast Cancer, drug libraries, partnerships, CPRIT Grant.